Literature DB >> 22974830

Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease.

Lisa A Maier, Briana Q Barkes, Margaret Mroz, Milton D Rossman, Juliana Barnard, May Gillespie, Allison Martin, Douglas G Mack, Lori Silveira, Richard T Sawyer, Lee S Newman, Andrew P Fontenot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22974830      PMCID： PMC4347848          DOI： 10.1016/j.rmed.2012.08.014

Source DB:  PubMed          Journal:  Respir Med        ISSN： 0954-6111            Impact factor:   3.415


× No keyword cloud information.
  28 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Deficient and dysfunctional regulatory T cells in the lungs of chronic beryllium disease subjects.

Authors:  Douglas G Mack; Allison M Lanham; Michael T Falta; Brent E Palmer; Lisa A Maier; Andrew P Fontenot
Journal:  Am J Respir Crit Care Med       Date:  2010-03-18       Impact factor: 21.405

Review 3.  Corticosteroid therapy in pulmonary sarcoidosis: a systematic review.

Authors:  Shanthi Paramothayan; Paul W Jones
Journal:  JAMA       Date:  2002-03-13       Impact factor: 56.272

4.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

5.  High beryllium-stimulated TNF-alpha is associated with the -308 TNF-alpha promoter polymorphism and with clinical severity in chronic beryllium disease.

Authors:  L A Maier; R T Sawyer; R A Bauer; L A Kittle; P Lympany; D McGrath; R Dubois; E Daniloff; C S Rose; L S Newman
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

6.  Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

Authors:  Gary R Lichtenstein; Songkai Yan; Mohan Bala; Stephen Hanauer
Journal:  Am J Gastroenterol       Date:  2004-01       Impact factor: 10.864

7.  Early pulmonary physiologic abnormalities in beryllium disease.

Authors:  G P Pappas; L S Newman
Journal:  Am Rev Respir Dis       Date:  1993-09

8.  Predicting mortality in patients with rheumatoid arthritis.

Authors:  Frederick Wolfe; Kaleb Michaud; Olaf Gefeller; Hyon K Choi
Journal:  Arthritis Rheum       Date:  2003-06

9.  Infliximab maintenance therapy for fistulizing Crohn's disease.

Authors:  Bruce E Sands; Frank H Anderson; Charles N Bernstein; William Y Chey; Brian G Feagan; Richard N Fedorak; Michael A Kamm; Joshua R Korzenik; Bret A Lashner; Jane E Onken; Daniel Rachmilewitz; Paul Rutgeerts; Gary Wild; Douglas C Wolf; Paul A Marsters; Suzanne B Travers; Marion A Blank; Sander J van Deventer
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

10.  Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy.

Authors:  Michael R Ehrenstein; Jamie G Evans; Animesh Singh; Samantha Moore; Gary Warnes; David A Isenberg; Claudia Mauri
Journal:  J Exp Med       Date:  2004-07-26       Impact factor: 14.307
View more
  8 in total

1.  5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects.

Authors:  Brian J Day; Jie Huang; Briana Q Barkes; May Gillespie; Li Li; Lisa A Maier
Journal:  Lung       Date:  2017-10-27       Impact factor: 2.584

2.  Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis.

Authors:  Li Li; Lori J Silveira; Nabeel Hamzeh; May Gillespie; Peggy M Mroz; Annyce S Mayer; Tasha E Fingerlin; Lisa A Maier
Journal:  Eur Respir J       Date:  2016-04-21       Impact factor: 16.671

Review 3.  Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease.

Authors:  Amy S McKee; Shaikh M Atif; Michael T Falta; Andrew P Fontenot
Journal:  J Immunol       Date:  2022-04-15       Impact factor: 5.426

4.  Effect of inhaled corticosteroids on lung function in chronic beryllium disease.

Authors:  Margaret M Mroz; John H Ferguson; Anna V Faino; Annyce Mayer; Matthew Strand; Lisa A Maier
Journal:  Respir Med       Date:  2018-02-05       Impact factor: 3.415

5.  A role for TNF-α in alveolar macrophage damage-associated molecular pattern release.

Authors:  Morgan K Collins; Abigail M Shotland; Morgan F Wade; Shaikh M Atif; Denay K Richards; Manolo Torres-Llompart; Douglas G Mack; Allison K Martin; Andrew P Fontenot; Amy S McKee
Journal:  JCI Insight       Date:  2020-05-07

Review 6.  Pulmonary Macrophage Cell Death in Lung Health and Disease.

Authors:  Abigail M Shotland; Andrew P Fontenot; Amy S McKee
Journal:  Am J Respir Cell Mol Biol       Date:  2021-05       Impact factor: 6.914

7.  Chronic Beryllium Disease: revealing the role of beryllium ion and small peptides binding to HLA-DP2.

Authors:  Marharyta Petukh; Bohua Wu; Shannon Stefl; Nick Smith; David Hyde-Volpe; Li Wang; Emil Alexov
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

8.  Sarcoidosis in a patient clinically diagnosed with silicosis; is silica associated sarcoidosis a new phenotype?

Authors:  Els Beijer; Bob Meek; Hans Kromhout; H Wouter van Es; Kees Seldenrijk; Marjolein Drent; Jos M Rooijackers; Marcel Veltkamp
Journal:  Respir Med Case Rep       Date:  2019-07-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.